We recently published a list of 12 Best Quality Stocks to Invest in Now. In this article, we are going to take a look at ...

Eli Lilly (NYSE: LLY) stock has had plenty of good trading sessions over the past year or so, but Monday's sure wasn't among ...

A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli ...

You can create a release to package software, along with release notes and links to binary files, for other people to use. Learn more about releases in our docs.

That negative investor reaction was directed at companies involved in the white-hot weight loss drug segment of the market (Eli Lilly is the pharmaceutical giant behind a popular one, Zepbound).

Presiding over the upward trajectory of Eli Lilly over the last eight years is paying off nicely for CEO David Ricks. | ...

A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...

RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark ...

Pull requests help you collaborate on code with other people. As pull requests are created, they’ll appear here in a searchable and filterable list. To get started, you should create a pull request.

14 at 5:15 p.m. Eastern time. Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound® (tirzepatide) as the first and only prescription ...